Skip to main content
. Author manuscript; available in PMC: 2021 Feb 1.
Published in final edited form as: Biol Blood Marrow Transplant. 2019 Sep 26;26(2):333–342. doi: 10.1016/j.bbmt.2019.09.027

Figure 1. Inclusion / Exclusion Criteria.

Figure 1.

The VPS and CIBMTR databases were queried and merged to produce the final study population of n=936 patients. 1,071 allogeneic HCT patients from VPS were successfully merged with CIBMTR records. Of these, 135 were excluded due to relapsed malignancy after HCT and prior to PICU admission. The final study population included 936 patients age <21 years admitted to a PICU between 1/1/2009–12/31/2014 each underwent a first allogeneic HCT in the USA/Canada between 1/1/2008–12/31/2014 and had not relapsed from primary disease at the time of PICU admission. These 936 patients accounted for 1,532 PICU admissions during the study interval.